Hara Koyu, Yaita Kenichiro, Khamrin Pattara, Kumthip Kattareeya, Kashiwagi Takahito, Eléouët Jean-François, Rameix-Welti Marie-Anne, Watanabe Hiroshi
Department of Infection Control and Prevention, Kurume University School of Medicine, Fukuoka, 830-0011, Japan.
Division of Infectious diseases, Chidoribashi General Hospital, Fukuoka 812-8633, Japan.
J Gen Virol. 2020 Jan;101(1):21-32. doi: 10.1099/jgv.0.001350.
Peptide-based inhibitors hold promising potential in the development of antiviral therapy. Here, we investigated the antiviral potential of fragmented viral proteins derived from ribonucleoprotein (RNP) components of the human respiratory syncytial virus (HRSV). Based on a mimicking approach that targets the functional domains of viral proteins, we designed various fragments of nucleoprotein (N), matrix protein M2-1 and phosphoprotein (P) and tested the antiviral activity in an RSV mini-genome system. We found that the fragment comprising residues 130-180 and 212-241 in the C-terminal region of P (81 amino acid length), denoted as P Fr, significantly inhibited the polymerase activity through competitive binding to the full-length P. Further deletion analysis of P Fr suggested that three functional domains in P Fr (oligomerization, L-binding and nucleocapsid binding) are required for maximum inhibitory activity. More importantly, a purified recombinant P Fr displayed significant antiviral activity at low nanomolar range in RSV-infected HEp-2 cells. These results highlight P as an important target for the development of antiviral compounds against RSV and other paramyxoviruses.
基于肽的抑制剂在抗病毒治疗的开发中具有广阔的前景。在此,我们研究了源自人类呼吸道合胞病毒(HRSV)核糖核蛋白(RNP)组分的片段化病毒蛋白的抗病毒潜力。基于靶向病毒蛋白功能域的模拟方法,我们设计了核蛋白(N)、基质蛋白M2-1和磷蛋白(P)的各种片段,并在RSV微型基因组系统中测试了其抗病毒活性。我们发现,P蛋白C端区域包含130-180和212-241位残基的片段(长度为81个氨基酸),记为P Fr,通过与全长P蛋白竞争性结合,显著抑制了聚合酶活性。对P Fr的进一步缺失分析表明,P Fr中的三个功能域(寡聚化、L蛋白结合和核衣壳结合)对于最大抑制活性是必需的。更重要的是,纯化的重组P Fr在低纳摩尔范围内对RSV感染的HEp-2细胞显示出显著的抗病毒活性。这些结果突出了P蛋白作为开发针对RSV和其他副粘病毒的抗病毒化合物的重要靶点。